Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$18.39 -1.2%	$18.14	$16.10 ▼ $42.47	$2.34B	0.68	2.34 million shs	1.07 million shs
BHC Bausch Health Cos	$6.38 +2.9%	$5.09	$3.96 ▼ $9.85	$2.29B	0.28	2.62 million shs	3.07 million shs
GMTX Gemini Therapeutics	$55.00 +6.4%	$47.72	$1.16 ▼ $14.10	$2.38B	-0.12	189,291 shs	561,392 shs
KALV KalVista Pharmaceuticals	$11.68 -0.2%	$12.50	$7.30 ▼ $15.50	$581.67M	-0.01	486,033 shs	1.30 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	-1.18%	+3.55%	+5.45%	-24.26%	-54.48%
BHC Bausch Health Cos	+2.99%	+3.02%	+43.21%	-5.40%	-6.18%
GMTX Gemini Therapeutics	+6.42%	+9.89%	+16.11%	+4.78%	+22.28%
KALV KalVista Pharmaceuticals	-0.17%	-5.12%	+1.83%	-5.35%	+1.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.7149 of 5 stars	4.3	3.0	0.0	4.4	3.2	2.5	0.6
BHC Bausch Health Cos	3.5092 of 5 stars	1.9	2.0	0.0	4.0	2.6	3.3	0.6
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.8853 of 5 stars	3.6	0.0	0.0	4.4	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$40.05	117.80% Upside
BHC Bausch Health Cos	1.86	Reduce	$7.42	16.25% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	112.61% Upside

Current Analyst Ratings Breakdown

Latest KALV, BHC, GMTX, and APLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00
5/9/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$75.00 ➝ $52.00
5/9/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$41.00 ➝ $23.00
5/8/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $18.00
5/8/2025	APLS Apellis Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$28.00 ➝ $20.00
5/8/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $26.00
5/8/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$55.00 ➝ $47.00
5/7/2025	APLS Apellis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $29.00
5/2/2025	BHC Bausch Health Cos	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$8.50 ➝ $10.00

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	2.96	N/A	N/A	$1.84 per share	9.99
BHC Bausch Health Cos	$9.63B	0.25	$7.98 per share	0.80	($0.89) per share	-7.17
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.37	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-104.25%	-78.69%	7/10/2025 (Estimated)

Latest KALV, BHC, GMTX, and APLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
BHC Bausch Health Cos	N/A	1.35	0.97
GMTX Gemini Therapeutics	N/A	71.49	71.49
KALV KalVista Pharmaceuticals	N/A	10.44	10.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
BHC Bausch Health Cos	78.65%
GMTX Gemini Therapeutics	75.42%
KALV KalVista Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
BHC Bausch Health Cos	8.05%
GMTX Gemini Therapeutics	12.90%
KALV KalVista Pharmaceuticals	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.51 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.29 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.50 million	Optionable

KALV, BHC, GMTX, and APLS Headlines

Recent News About These Companies

FDA's Makary sought to reject KalVista’s drug: report

June 24 at 8:38 PM | msn.com

KalVista Pharmaceuticals (NASDAQ:KALV) Sees Large Volume Increase - Here's Why

June 24 at 4:39 PM | marketbeat.com

How KalVista Pharma Is Taking On A Rare But Deadly Disease

June 20, 2025 | msn.com

FDA delays decision on hereditary disease drug

June 18, 2025 | beckershospitalreview.comB

KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down - What's Next?

June 16, 2025 | marketbeat.com

Makary Considers More Cuts at FDA Amid Continued Delays

June 16, 2025 | biospace.comB

FDA Plans to Shrink; Nursing Shortage at Walter Reed; Pelvic Floor Therapy for Men?

June 16, 2025 | medpagetoday.comM

DOGE cuts cause FDA to delay decision on hereditary disease drug

June 16, 2025 | msn.com

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

June 16, 2025 | biopharmadive.comB

KalVista Pharmaceuticals Shares Edge Down on FDA Delays for Sebetralstat Application

June 16, 2025 | marketwatch.com

FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision

June 16, 2025 | fiercebiotech.comF

FDA won’t meet PDUFA goal date for sebetralstat

June 14, 2025 | thepharmaletter.comT

FDA Tells Drugmaker ‘Heavy Workload’ to Delay Approval Decision

June 13, 2025 | bloomberg.com

DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals’ Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints

June 13, 2025 | cantechletter.comC

KalVista said FDA will not meet review date for sebetralstat

June 13, 2025 | msn.com

Health Sector Updates: Breakthroughs and Challenges

June 13, 2025 | devdiscourse.comD

KalVista Pharmaceuticals Hit by FDA Delays

June 13, 2025 | marketwatch.com

US FDA extends review of KalVista's swelling disorder drug due to heavy workload

June 13, 2025 | reuters.com

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

June 13, 2025 | businesswire.com

Cantor Fitzgerald Comments on KALV FY2026 Earnings

June 11, 2025 | marketbeat.com

Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells 7,169 Shares of Stock

June 11, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV, BHC, GMTX, and APLS Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$18.39 -0.22 (-1.18%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$18.39 0.00 (-0.03%)

As of 06/25/2025 07:42 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Bausch Health Cos NYSE:BHC

$6.38 +0.18 (+2.90%)

Closing price 06/25/2025 03:59 PM Eastern

Extended Trading

$6.39 +0.01 (+0.16%)

As of 06/25/2025 06:55 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Gemini Therapeutics NASDAQ:GMTX

$55.00 +3.32 (+6.42%)

As of 06/24/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

KalVista Pharmaceuticals NASDAQ:KALV

$11.68 -0.02 (-0.17%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$12.20 +0.53 (+4.49%)

As of 04:00 AM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time